Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes
Authors Zhao M, Zhao M, Fu C, Yu Y, Fu A
Received 14 November 2017
Accepted for publication 24 January 2018
Published 15 March 2018 Volume 2018:13 Pages 1601—1610
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 2
Editor who approved publication: Dr Linlin Sun
Ming Zhao,* Mengnan Zhao,* Chen Fu, Yang Yu, Ailing Fu
School of Pharmaceutical Sciences, Southwest University, Chongqing, People’s Republic of China
*These authors contributed equally to this work
Background: Glioma is the most aggressive and lethal brain tumor in humans, it comprises about 30 per cent of all brain tumors and central nervous system tumors.
Purpose: The objective of this study was to create novel brain-targeting nanoliposomes to encapsulate curcumin as a promising option for glioma therapy.
Patients and methods: Human glioma cells (U251MG) were used to determine cell uptake efficiency and possible internalization mechanism of the curcumin-loaded nanoliposomes modified by a brain-targeting peptide RDP. In addition, intracranial glioma mice model was prepared by transplantation of U251MG cells into the mice striatum, and then the liposomes were intravenously administered into the glioma-bearing mice to evaluate the anti-glioma activity.
Results: RDP-modified liposomes (RCL) could enter the brain and glioma region, and were internalized by the glioma cells perhaps through acetylcholine receptor-mediated endocytosis pathway. Furthermore, the RCL prolonged the survival time of the glioma-bearing mice from 23 to 33 days, and the inhibition mechanism of the RCL on glioma cell was partly due to cell cycle arrest at the S phase and induction of cell apoptosis.
Conclusion: This study would provide a potential approach for targeted delivery of drug-loaded liposomes for glioma treatment.
Keywords: glioma, targeted delivery, cell apoptosis, cell cycle, survival time
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]